488 related articles for article (PubMed ID: 17351764)
1. The proprotein convertases are potential targets in the treatment of dyslipidemia.
Seidah NG; Prat A
J Mol Med (Berl); 2007 Jul; 85(7):685-96. PubMed ID: 17351764
[TBL] [Abstract][Full Text] [Related]
2. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.
Seidah NG; Abifadel M; Prost S; Boileau C; Prat A
Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219
[TBL] [Abstract][Full Text] [Related]
3. The proprotein convertases and their implication in sterol and/or lipid metabolism.
Seidah NG; Khatib AM; Prat A
Biol Chem; 2006 Jul; 387(7):871-7. PubMed ID: 16913836
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertases: lessons from knockouts.
Scamuffa N; Calvo F; Chrétien M; Seidah NG; Khatib AM
FASEB J; 2006 Oct; 20(12):1954-63. PubMed ID: 17012247
[TBL] [Abstract][Full Text] [Related]
5. The activation and physiological functions of the proprotein convertases.
Seidah NG; Mayer G; Zaid A; Rousselet E; Nassoury N; Poirier S; Essalmani R; Prat A
Int J Biochem Cell Biol; 2008; 40(6-7):1111-25. PubMed ID: 18343183
[TBL] [Abstract][Full Text] [Related]
6. The proprotein convertases, 20 years later.
Seidah NG
Methods Mol Biol; 2011; 768():23-57. PubMed ID: 21805237
[TBL] [Abstract][Full Text] [Related]
7. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
8. What lies ahead for the proprotein convertases?
Seidah NG
Ann N Y Acad Sci; 2011 Mar; 1220():149-61. PubMed ID: 21388412
[TBL] [Abstract][Full Text] [Related]
9. The biology and therapeutic targeting of the proprotein convertases.
Seidah NG; Prat A
Nat Rev Drug Discov; 2012 May; 11(5):367-83. PubMed ID: 22679642
[TBL] [Abstract][Full Text] [Related]
10. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Shen L; Peng H; Xu D; Zhao S
Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
[TBL] [Abstract][Full Text] [Related]
11. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system.
Poirier S; Prat A; Marcinkiewicz E; Paquin J; Chitramuthu BP; Baranowski D; Cadieux B; Bennett HP; Seidah NG
J Neurochem; 2006 Aug; 98(3):838-50. PubMed ID: 16893422
[TBL] [Abstract][Full Text] [Related]
12. Proprotein convertases regulate trafficking and maturation of key proteins within the secretory pathway.
Cendron L; Rothenberger S; Cassari L; Dettin M; Pasquato A
Adv Protein Chem Struct Biol; 2023; 133():1-54. PubMed ID: 36707198
[TBL] [Abstract][Full Text] [Related]
13. How Do Enveloped Viruses Exploit the Secretory Proprotein Convertases to Regulate Infectivity and Spread?
Seidah NG; Pasquato A; Andréo U
Viruses; 2021 Jun; 13(7):. PubMed ID: 34202098
[TBL] [Abstract][Full Text] [Related]
14. The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions.
Seidah NG; Sadr MS; Chrétien M; Mbikay M
J Biol Chem; 2013 Jul; 288(30):21473-81. PubMed ID: 23775089
[TBL] [Abstract][Full Text] [Related]
15. The proprotein convertases furin and PACE4 play a significant role in tumor progression.
Bassi DE; Mahloogi H; Klein-Szanto AJ
Mol Carcinog; 2000 Jun; 28(2):63-9. PubMed ID: 10900462
[TBL] [Abstract][Full Text] [Related]
16. The Role of Proprotein Convertases in the Regulation of the Function of Immune Cells in the Oncoimmune Response.
Rose M; Duhamel M; Rodet F; Salzet M
Front Immunol; 2021; 12():667850. PubMed ID: 33995401
[TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
[TBL] [Abstract][Full Text] [Related]
18. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).
Schulz R; Schlüter KD; Laufs U
Basic Res Cardiol; 2015 Mar; 110(2):4. PubMed ID: 25600226
[TBL] [Abstract][Full Text] [Related]
19. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
Kourimate S; Le May C; Langhi C; Jarnoux AL; Ouguerram K; Zaïr Y; Nguyen P; Krempf M; Cariou B; Costet P
J Biol Chem; 2008 Apr; 283(15):9666-73. PubMed ID: 18245819
[TBL] [Abstract][Full Text] [Related]
20. New developments in atherosclerosis: clinical potential of PCSK9 inhibition.
Giunzioni I; Tavori H
Vasc Health Risk Manag; 2015; 11():493-501. PubMed ID: 26345307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
